VCYT 40.89 (+4.66%)
US92337F1075BiotechnologyBiotechnology

Veracyte (VCYT) Stock Highlights

40.89 | +4.66%
2024-12-21 03:08:27
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firms product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis product.

Statistics

Range Today
38.44 41.38
Volume Today 2.01M
Range 1 Year
18.61 46
Volume 1 Year 191.6M
Range 3 Year
14.85 46
Volume 3 Year 594.25M
Range 10 Year
4.21 86.03
Volume 10 Year 1.22B

Highlights

Market Capitalization 2.83B (mid)
Floating Shares 76.66M
Current Price 40.89
Price To Earnings -285.77
Price To Revenue 6.16
Price To Book 2.39
Earnings Per Share -0.13
Payout Ratio 0%

Performance

Latest +4.66%
1 Month +4.42%
3 Months +16.9%
6 Months +92.7%
1 Year +42.72%
3 Years -6.56%
5 Years +40.42%
10 Years +389.7%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.